Announcements Trials
Browse Landscape

Phase

Phase NA 8Phase 3 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 551Colorectal Neoplasms 246Neoplasms 232Prostatic Neoplasms 221Carcinoma, Non-Small-Cell Lung 196Stomach Neoplasms 153Leukemia, Myeloid, Acute 149Carcinoma, Hepatocellular 147Lung Neoplasms 136Rectal Neoplasms 135Multiple Myeloma 132Nasopharyngeal Carcinoma 111Colonic Neoplasms 106Neoplasm Metastasis 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Lymphoma 85Uterine Cervical Neoplasms 83Pancreatic Neoplasms 82Lymphoma, Large B-Cell, Diffuse 79Ovarian Neoplasms 78Leukemia 78Head and Neck Neoplasms 77Esophageal Neoplasms 74Lymphoma, Follicular 72Brain Neoplasms 70Squamous Cell Carcinoma of Head and Neck 65Recurrence 64Leukemia, Lymphocytic, Chronic, B-Cell 59Lymphoma, Non-Hodgkin 58Pain 56

Interventions

enzalutamide 1apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × OTHER × Patient Preference × Clear all
NCT04409288 2024-01-05

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Chinese University of Hong Kong

Phase 3 Terminated
74 enrolled
Genitourinary

Prostatic Neoplasms, Patient Preference

NCT01906073 2020-12-10

NFCP-2

Norwegian University of Science and Technology

Phase 3 Withdrawn

Neoplasms, Pain, Patient Satisfaction, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡